

## CLAIM AMENDMENTS

1           1. (currently amended) A therapeutic agent having a  
2 ~~destructive effect on malignant tumors~~ which comprises as  
3 therapeutically effective ingredients: alpha-ketoglutaric acid or its  
4 pharmaceutically effective salts and at least one compound promoting  
5 azomethine solution formation in an enzyme independent reaction and  
6 selected from the group consisting of 5-hydroxymethyl-furfural,  
7 dehydroascorbic acid, malt and vanillin, whereby the mass ratio of the  
8 ketoglutaric acid to the at least azomethine formation promoting  
9 compound is greater than 1:1 wherein the therapeutic agent contains as  
10 further therapeutically effective ingredients:  
11 N-acetyl-seleno-L-methionine and N-acetyl-L-methionine whereby the  
12 latter is present in excess with respect to the former.

1           2. (previously presented) The therapeutic agent according  
2 to claim 1 characterized in that the mass ratio of alpha-ketoglutaric  
3 acid to N-acetyl-seleno-L-methionine is 100:1 to 20000:1.

1           3. (previously presented) The therapeutic agent according  
2 to claim 1 wherein the mass ratio of N-acetyl-seleno-L-methionine is  
3 20:1 to 300:1.

1           4. (Previously presented) The therapeutic agent according  
2 to claim 1 wherein it further comprises glucose, fructose or a mixture  
3 thereof.

1           5. (Currently amended) The therapeutic agent according to  
2 claim 1 wherein the compound promoting ~~azomethionine~~ azomethine  
3 formation is 5-hydroxymethylfurfural.

1           6. (Previously presented) The therapeutic agent according  
2 to claim 1, wherein it is put up in an aqueous solution and the N-  
3 acetyl-seleno-L-methionine is present in an amount of 1.4 to 2.3 mg/l  
4 and the N-acetyl-L-methionine is present in an amount of 70 to 230  
5 mg/l.

1           7. (Previously presented) The therapeutic agent according  
2 to claim 4 wherein it contains an electrolyte from the group of sodium  
3 or potassium.

1           8. (Previously presented) The therapeutic agent according  
2 to claim 1 wherein it is administered intravenously and has a pH value  
3 of 4 to 6.

1           9. (Previously presented) The therapeutic agent according  
2 to claim 4 or claim 7 wherein the alpha-ketoglutaric acid is present in  
3 a concentration of 3 to 20 g/l, the compound promoting azomethionine  
4 formation is 5-hydroxymethylfurfural present in a concentration of 1 to  
5 3 g/l, the glucose is present in a concentration of 20 to 100 g/l, the  
6 sodium ion is present in a concentration of 60 to 160 mmol/l and the  
7 potassium ion is present in a concentration of 15 to 40 mmol/l.

1           10. (Previously presented) The therapeutic agent according  
2 to claim 9 wherein the alpha-ketoglutaric acid is present in a

3 concentration of 6 to 16 g/l, 5-hydroxymethylfurfural is present in a  
4 concentration of 1 to 2.5 g/l, the glucose in a concentration of 20 to  
5 50 g/l, the sodium ion in a concentration of 70 to 160 mmol/l and the  
6 potassium ion is present in a concentration of 20 to 40 mmol/l.

1 11. (previously presented) The therapeutic agent according  
2 to claim 1 which is put up in a solid or liquid or oral or rectal  
3 administration dosage form which contains the ketoglutaric acid at  
4 least in part in the form of a monosodium or monopotassium salt  
5 thereof.

1 12. (Previously presented) The therapeutic agent according  
2 to claim 11 which further comprises a lubricating agent and/or extender  
3 and/or a taste improving disaccharide.

1 13. (Previously presented) The therapeutic agent according  
2 to claim 11 which comprises in the dosage unit 3 to 9 g of alpha-  
3 ketoglutaric acid, 0.5 to 1.5 g 5-hydroxymethyl-furfural, 1.4 to 2.3 mg  
4 N-acetyl-seleno-L-methionine and 70 to 230 mg of  
5 N-acetyl-L-methionine.

1 14. (Withdrawn) A method of making a therapeutic agent in  
2 a form suitable for intravenous administration according to claim 8  
3 wherein the alpha-ketoglutaric acid is dissolved at elevated  
4 temperature in distilled water which has had its oxygen content reduced  
5 by a gasification and glucose or fructose added to it together with  
6 alkalies other than ammonia or amines, the pH being adjusted to be

7 somewhat above 4 and N-acetyl-seleno-L-methionine, N-acetyl-L-  
8 methionine and the compound promoting azomethine formation.

1 15. (withdrawn) A method of making a preparation suitable  
2 for oral or rectal administration according to claim 11 wherein to  
3 adjust the pH from 3 to 6 the ketoglutaric acid is partly to entirely  
4 used in the form of its monosalt with sodium and/or potassium and in  
5 which extenders and if desired also disaccharides are mixed therewith  
6 and to this mixture the compound promoting azomethine formation, the N-  
7 acetyl-seleno-L-methionine and the N-acetyl-L-methionine are added  
8 whereupon the mixture is put up in the desired form of administering  
9 especially as a particule granulate, in tablets, or in an irrigating  
10 liquid.

16. (canceled)

17. (canceled)

1 18. (withdrawn) A cytocidal method of treating a malignant  
2 tumor in a patient afflicted with said malignant tumor which comprises  
3 the step of administering to said patient, an amount of the therapeutic  
4 agent defined in claim 1, effective to treat the malignant tumor.

1 19. (withdrawn) The cytocidal method of treating a malignant  
2 tumor defined in claim 18 wherein the therapeutic agent is administered  
3 to the patient orally, rectally, in the form of an irrigation, or as an  
4 intravenous infusion.

1           20. (withdrawn) The cytocidal method of treating a  
2 malignant tumor defined in claim 19 wherein the therapeutic agent is  
3 administered to the patient as an intravenous infusion.

1           21. (Currently amended) A therapeutic agent ~~for the~~  
2 ~~cytotoxic treatment of a malignant tumor~~ administrable as an  
3 intravenous infusion, which consists essentially of:

4   alpha-ketoglutaric acid	6 - 16 g/l
5   5-hydroxymethylfurfural	1.0 - 2.5 g/l
6   N-acetyl-seleno-L-methionine	1.4 - 2.3 mg/l
7   N-acetyl-L-methionine	70 - 230 mg/l
8   glucose	20 - 50 g/l
9   sodium ion	70 - 160 mmol/l and
10   potassium ion	20 - 40 mmol/l
11   in combination with a pharmaceutically acceptable inert carrier	
12   suitable for intravenous administration.	

1           22. (withdrawn) A cytotoxic method of treating a malignant  
2 tumor in a patient afflicted with said malignant tumor which comprises  
3 the step of administering to said patient, by intravenous infusion, an  
4 amount of the therapeutic agent defined in claim 21, effective to treat  
5 the malignant tumor.